Leaderboards/Pharmaceutical Practices and Patient Outcomes

Pharmaceutical Practices and Patient Outcomes

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Samantha Valliant
Daiichi Sankyo (United States)
2
Jenny S. Guadamuz
University of California, Berkeley
3
Guo‐Li Xiong
King University
4
Hernán Ramos
Universitat de València
5
Sineenart Chautrakarn
Faculty of Public Health
6
Mostafa Mohamed
University of Rochester
7
Pendo Ndaki
Catholic University of Health and Allied Sciences
8
Clara H. Heinrich
University College Cork
9
Kate Traynor
Unknown
10
Judith A. Koecheler
MetroHealth

Rising Stars Papers

1
Indicators for the Selection of Ambulatory Patients Who Warrant Pharmacist Monitoring
American Society of Health-System Pharmacists eBooks|2025
98 cit.
2
More US Pharmacies Closed Than Opened In 2018–21; Independent Pharmacies, Those In Black, Latinx Communities Most At Risk
Health Affairs|2024
32 cit.
3
Primary Treatment Modification and Treatment Tolerability Among Older Chemotherapy Recipients With Advanced Cancer
JAMA Network Open|2024
23 cit.
4
Mental health and sleep in the post-COVID-19 era among Thai undergraduate students
Scientific Reports|2024
12 cit.
5
Racialized economic segregation and inequities in treatment initiation and survival among patients with metastatic breast cancer
Breast Cancer Research and Treatment|2024
10 cit.
6
Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023
JNCI Cancer Spectrum|2024
7 cit.
7
Effect of polypharmacy and potentially inappropriate medications on physical functional decline among older adults with advanced cancer receiving systemic treatment
Supportive Care in Cancer|2024
5 cit.
8
Sociodemographic inequities in COVID-19 vaccination among adults in the United States, 2022
Journal of the American Pharmacists Association|2024
2 cit.
9
Stress and work-related accidents among food delivery riders in Chiang Mai, Thailand
Journal of Health Research|2024
2 cit.
10
<i>DPYD</i> testing makes fluoropyrimidine chemotherapy safer
American Journal of Health-System Pharmacy|2024
1 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Nicole L. Olenik
Purdue University West Lafayette
2
Denis Curtin
Cork University Hospital
3
Inmaculada Hernandez
University of California San Diego
4
Kym Moline
Mercy Health Saint Mary's
5
TJ Walsh
University of Notre Dame
6
Jonas W. Wastesson
Karolinska Institutet
7
Kalyan C. Nagulapalli Venkata
University of Health Sciences and Pharmacy
8
Mary Mcclurg
University of North Carolina at Chapel Hill
9
Fernanda S. Tonin
Universidad de Granada
10
Frank Moriarty
Royal College of Surgeons in Ireland

Emerging Leaders Papers

1
STOPP/START criteria for potentially inappropriate prescribing in older people: version 3
European Geriatric Medicine|2023
681 cit.
2
Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis
Journal of the American Pharmacists Association|2022
329 cit.
3
Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system–based cross-sectional study
PLoS Medicine|2022
64 cit.
4
A Prescription for Achieving Equitable Access to Antiobesity Medications
JAMA Health Forum|2023
40 cit.
5
Improving the quality of publications in and advancing the paradigms of clinical and social pharmacy practice research: the Granada Statements
International Journal of Clinical Pharmacy|2023
37 cit.
6
Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
JAMA Network Open|2022
36 cit.
7
Use of ‘Pharmaceutical services’ Medical Subject Headings (MeSH) in articles assessing pharmacists' interventions
Exploratory Research in Clinical and Social Pharmacy|2022
30 cit.
8
Improving the quality of publications in and advancing the paradigms of clinical and social pharmacy practice research: The Granada statements
Research in Social and Administrative Pharmacy|2023
30 cit.
9
Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries
JAMA Network Open|2023
29 cit.
10
Assessment of Commercial and Mandatory Discounts in the Gross-to-Net Bubble for the Top Insulin Products From 2012 to 2019
JAMA Network Open|2023
24 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Denis O’Mahony
University College Cork
2
David W. Bates
Brigham and Women's Hospital
3
Matthew Hankins
Truven Health Analytics (United States)
4
E Sabaté
Gilead Sciences (United States)
5
Timothy F. Chen
The University of Sydney
6
Brian S. Mittman
Kaiser Permanente
7
Carmel Hughes
Queen's University Belfast
8
Sarah N. Hilmer
Northern Sydney Local Health District
9
Liana Fraenkel
Berkshire Medical Center
10
David G. Le Couteur
Concord Hospital

Current Senior Leaders Papers

1
Adherence to Long‐Term Therapies: Evidence for Action
Journal of Nursing Scholarship|2003
2.6k cit.
2
The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication
Psychology and Health|1999
2.4k cit.
3
Welcome to Implementation Science
Implementation Science|2006
2.3k cit.
4
Incidence of Adverse Drug Events and Potential Adverse Drug Events
JAMA|1995
2.1k cit.
5
Effect of Computerized Physician Order Entry and a Team Intervention on Prevention of Serious Medication Errors
JAMA|1998
2.1k cit.
6
Implementation Research in Mental Health Services: an Emerging Science with Conceptual, Methodological, and Training challenges
Administration and Policy in Mental Health and Mental Health Services Research|2008
1.9k cit.
7
The Incidence and Severity of Adverse Events Affecting Patients after Discharge from the Hospital
Annals of Internal Medicine|2003
1.9k cit.
8
Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting
JAMA|2003
1.7k cit.
9
Improving Safety with Information Technology
New England Journal of Medicine|2003
1.5k cit.
10
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group
JAMA|1997
1.4k cit.

Reagents for Pharmaceutical Practices and Patient Outcomes

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

CASK Antibody

#2878$317
View Evidence →
Cell Signaling TechnologyEvidence 61

Mm47 (F4E5V) Rabbit Monoclonal Antibody

#74986$161,376
View Evidence →
Cell Signaling TechnologyEvidence 67

RIP3 (D8J3L) Rabbit Monoclonal Antibody (BSA and Azide Free)

#92131$865
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

SMAD2/3 (D7G7) Rabbit Monoclonal Antibody (SignalFlex™ mFluor™ Red 780 Conjugate)

#75214$458
View Evidence →
Cell Signaling TechnologyEvidence 66

MO25 alpha/CAB39 (C49D8) Rabbit Monoclonal Antibody

#2716$158,348
View Evidence →
Cell Signaling TechnologyEvidence 67

Catenin delta-1 (D7S2M) Rabbit Monoclonal Antibody

#59854$177,413
View Evidence →